David P. King
Known title: DirectorCIK: 0001275654
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Privia Health to Report Q3 2026 Results on Nov 5. Privia Health Group is scheduled to announce its third-quarter 2026 financial results on November 5. Recent coverage highlights the company's role in healthcare automation aimed at reducing administrative costs. With the stock currently trading near its support level, investors will be watching the earnings report for updates on revenue trends and cost management.
Transaction History
| ILMN | ▲ Buy | Grant | 2,072 | $300K | 5/21/2026 | View on chart |
| PRVA | ▲ Buy | Grant | 8,463 | $0 | 5/20/2026 | View on chart |
| PRVA | ▲ Buy | Grant | 8,396 | $0 | 5/21/2025 | View on chart |
| PRVA | ▲ Buy | Grant | 11,124 | $0 | 5/22/2024 | View on chart |
| PRVA | ▲ Buy | Grant | 7,758 | $0 | 7/1/2023 | View on chart |
| PRVA | ▲ Buy | Grant | 7,425 | $0 | 5/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends
Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.